American doctors and hospitals still send patient records by fax. Consensus runs the fax number over the internet and delivers each fax as a file, an e-mail or an entry in the patient's record.
The company · 2 · What exactly does it sell?
Two-thirds from big organisations, a third from small offices
Each $1 of sales, second quarter 2026
66%34%
Hospitals, firms and agenciesSmall and home offices
Corporate customers brought in $222.682M in 2025 and are growing; small offices brought in $127.002M and are shrinking.
The company · 3 · How does it make money?
Customers pay by the month, so keeping them is everything
$91.0Mthird-quarter sales, paid as monthly subscriptions
$301spent a month by each corporate account
$38.6Mof spare cash in one quarter
Cloud fax is nearly all of Consensus's sales and profit. It turns that steady income into cash to pay down a large debt.
Is it a good business? · 4 · What gives it an edge?
Security approvals thin the field, but are no longer rare
February 2025
it won the top federal security grade
etherFAX
a private rival, matched it in November 2025
Selling fax to a federal agency or a hospital needs a slow, costly security approval, which keeps rivals out. But a rival now holds two agency approvals to its one.
Is it a good business? · 5 · What is the catch?
Fax is being replaced, not just undercut
11networks chosen to carry records instead
Kno2one of them, sells fax as a feature; Consensus is not among them
3.87%of corporate customers leave each month
Listed rivals: OTEX
Federal rules push healthcare toward records that pass straight between computer systems. Corporate customers now leave about twice as fast as in 2023.
Is it a good business? · 6 · What does its record show?
Sales have barely moved in five years
Sales, $M
352.7
362.4
362.6
350.4
349.7
357.9
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$349.7Min 2025, about where 2021 was
Corporate, 2025$222.7Mgrowing, but costly to win
Small offices, 2025$127.0Mshrinking every year
Staff and selling costs now rise faster than sales, so Consensus keeps a little less of each dollar as the corporate side grows.
Is it a good business? · 7 · How much room is there to grow?
About 105,600 doctors relied on fax in 2019
About 35%of office doctors shared records only by fax or mail, 2019
78% to 79%of hospitals filing records electronically since 2022
Nobody has counted doctors since 2019. Hospitals' move to electronic records has stalled since 2022. That stall is the room fax still has.
Is it a good business? · 8 · Who is in charge?
Paid on sales and profit, not on keeping customers
Since 2021Scott Turicchi as chief executive
Under 4%of the shares owned by insiders
His big share award pays only if the stock rises far above today. Nothing in pay rewards keeping customers or cutting debt.
The story right now · 9 · Why do doctors still use fax?
Hospital computer systems still cannot talk to each other
11networks now designated to carry records
Veterans Affairsits flagship customer, through a contractor
Fax survives because hospitals' and doctors' systems cannot exchange records, as Consensus's own filing says. The government wants that fixed, which would make fax unnecessary.
The story right now · 10 · How can sales grow while customers leave?
Sales grow mostly because the shrinking half is smaller
Two halvesCorporate grows; small offices shrink.
Small offices fall awayA smaller drag each year.
Total sales tick upThe headline improves.
Yet more customers leave3.87% a month, from 3.16%.
So a rising sales line can hide a business getting weaker. The number to watch is how many corporate customers leave each month.
The story right now · 11 · What changed lately?
Sales rose 3.7%, but customers left faster
$91.0Mquarterly sales, up 3.7%
$38.6Mspare cash in the quarter
3.87%corporate customers lost a month, from 3.16%
$301spent per account, from $305
Mixed quarter
The shares rose 37.7% in a year while sales per share rose 3.1%, so nearly all the rise was buyers paying more for the same sales.
The story right now · 12 · What is everyone arguing about?
Is growth returning, or just arithmetic?
Many investors think
Corporate growth heading to double digits
We think
Weakening under a headline that improves
All four analysts are positive. We are wrong if customer losses fall back toward 2% a month and a second federal agency signs.
The price and our view · 13 · What is a share worth?
The price sits below even our gloomy future
$79.57what we think a share is worth · the last close is of that
$79.57our value
Attractive below $63.66
Neutral
Unattractive above $95.48
$54.55gloomy: growth halves and profit per sale slips
$79.57our estimate: experts' forecasts, then slowing
$115sunny: growth runs a quarter faster
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
Customers leaving, and one federal order not its own
Customers leaving fasterBiggest
Corporate losses rose every year since 2023.
Growth relabelledShowing now
A small-office product counts as corporate.
Debt due in 2028Watch
$348M, covered by a new loan.
The Veterans Affairs moneyUnknown
How much reaches Consensus is not said.
The Veterans Affairs order belongs to a contractor, and Consensus holds no federal contract of its own.
The price and our view · 15 · How will we know?
February shows if September was a one-off
Corporate customer losses under 3.5% a monthGood sign
Under 3.5%, more spent per account, corporate sales up 9%We turn positive
Veterans Affairs stops buying, or the approval is lostWe turn negative
FEB 202726
Fourth-quarter 2026 results. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: we turn negative if the shares rise a fifth above our estimate.
The price and our view · 16 · So, what do we think?
A cash machine tied to a technology being retired
$79.57our value
Attractive below $63.66
Neutral
Unattractive above $95.48
NeutralMedium conviction
Consensus runs internet fax for American doctors and hospitals, and turns it into steady cash against a large debt. The price sits below even our gloomy future, but customers leave faster than ever, so we stay Neutral.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Doctors and hospitals in America still send patient records by fax. Consensus runs the fax number over the internet: it handles the telephone side and delivers the document as a file, an e-mail or an entry in the patient's electronic record.
Without it, a customer keeps a fax machine on a phone line or a fax server in its own building. Cloud fax is substantially all of Consensus's revenue and profit.
How it makes money
Customers pay by the month. Corporate customers brought in $222.682M in 2025 and are growing; small-office customers brought in $127.002M and are shrinking.
What keeps the money coming is that customers stay, and that has weakened. Corporate customers now leave at 3.16% a month, against 1.49% in 2023; small-office customers at 4.69%.
Growth and profit
What growth costs
For years sales barely grew, so costs held steady per dollar of sales. Now that business customers are growing again, spending on staff and selling is rising faster than sales, so each new dollar of growth is making the company a little less profitable rather than more.
Its record
The numbers
Is it growing?Slow
Sales grew 2.4% over the twelve months to Sep 2026, about the same pace as the −0.2% in the year to Dec 2025.
Is it profitable?Strong
Operating margin is 41%, about where it was (41%) in the year to Dec 2023.
Does growth pay off?Costly
Running costs take 39¢ of each sales dollar, up from 34¢ in the year to Dec 2021.
Does it earn good returns?Decent
Each dollar put into the business earns 19% a year after tax, about where it was (17%) in the year to Dec 2021.
Is it making cash?Strong
It turned 31% of sales into free cash, $110M over the last twelve months.
Is the balance sheet safe?Heavy debt
It owes $443M more than the cash it holds, about 3.2 years of the cash its operations bring in.
Are shares being diluted?Stable
The share count fell 4.7% in 4.8 years, and pay in shares costs 5.9% of sales.
Why it wins
The evidence
Selling fax to a federal agency needs a government security approval; selling it to a hospital needs passing that hospital's security review. Both are slow and expensive to win, so they thin the field of who may bid. Fax itself survives because healthcare runs on systems that cannot talk to each other, as the company's own filing says.
The approval is no longer rare. Consensus got the top federal grade in February 2025; a private rival matched it in November 2025 and holds two agency approvals to its one.
Who could beat it
The rivals in full
The larger threat is what fax is being replaced by. Federal rules push healthcare toward records that pass directly between computer systems. Eleven networks are designated to carry them; Consensus is not one, and one that is, Kno2, sells fax as a feature inside its own platform. OpenText says its own cloud fax is heading for federal approval too.
Each rival
etherFAX GovCloudprivate
A federal buyer no longer has to choose Consensus to get an authorised cloud fax service; the same Class D (High) certification is available from another vendor, with more agency authorisations behind it.
OpenText Core Fax and OpenText Fax Cloud ConnectOTEX
The on-premise RightFax customer that Consensus is trying to convert can move to cloud fax without leaving its existing vendor, so the conversion Consensus calls its main growth engine never reaches the market.
Kno2private
The buyer stops purchasing fax as a standalone service and buys it as one transport option inside an interoperability platform, so the fax line becomes a feature of somebody else's product rather than a purchase of its own.
Epic Nexusprivate
The hospital's exchange with outside organisations moves into the network run by the electronic health record vendor it already pays, so no separate document transport is bought at all.
How big it could get
The market and who has signed
The market
In 2019 about 35% of roughly 301,603 American office-based doctors could share patient records outside their practice only by fax, mail or e-fax: about 105,600 doctors. Nobody has counted since, so it may be fewer now.
Hospitals set the other limit. The share that file an electronic record without retyping it rose from 40% in 2014 to 71% in 2019, and has sat at 78% to 79% since 2022. That stall is the room fax still has.
Who has signed
The one big contract is not Consensus's own. Veterans Affairs buys cloud fax through a contractor, Cognosante, one year at a time: on 16 September 2026 it renewed to September 2027, committing $15,953,229.56 against $12,338,013.36 the year before, with options to 2031. Management expects more than $9M of revenue from it this year.
Who runs it
Leaders, pay and the cash
Who runs it
Scott Turicchi has run Consensus since it was spun out in 2021; before that he ran the parent's finances. A new finance chief took over in April 2026. Insiders own under 4%, Turicchi the most. The yearly bonus pays on sales and on profit before stock pay; his big shares award pays only if the stock rises far above today's price. Nothing pays on keeping customers or paying down debt.
What they did with the money
From 2023 to 2025 it bought back shares for $47.9M and issued new ones to staff, so the count fell 4.8%. Staff are paid about $20M a year in shares, about a fifth of the spare cash, while revenue did not grow.
The last report
The latest report
Consensus' sales rose 3.7%, but corporate customers left faster and paid less
What it did to the thesis Mixed quarter
Sales and cash profit held and the guide rose, but the test of whether corporate growth is real went the wrong way: more customers left and each paid less. The cash is still real, so the view stays Neutral; one more quarter of heavy losses would break the case.
The report
In the September quarter sales rose 3.7% to $91.0M: corporate up 9.1%, small office down 6.0%. Corporate customers left at 3.87% a month, up from 3.16% in June and 2.73% a year earlier, and each paid $301 a month against $305 in June.
Cash profit rose 2.7% to $47.6M and free cash flow was $38.6M. Management narrowed its year's sales guide to $360M-$364M, raised earnings per share guidance to $6.00-$6.10 and bought back 550,000 shares.
What's happening now
The background
The shares rose 37.7% in a year while sales per share rose 3.1%, so nearly all the rise was buyers paying more for the same sales. The September-quarter report on 5 November was the test: corporate customers left faster, not slower, and each paid slightly less.
Where we disagree
Both sides in full
The market
Corporate growth is heading to double digits, and the shrinking half has nearly finished shrinking.
We believe
The business is weakening under a headline that improves. The improvement is arithmetic, but the cash is real, so the price is roughly fair.
The argument
All four analysts are positive. Three facts sit in federal registers rather than in the company's filings: a rival matched its security approval, its flagship customer is a contractor's order, and corporate customers leave twice as fast as in 2023.
We are wrong if those losses fall back toward 2% a month, spend per account rises two quarters running, and a second federal agency signs.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
The three cases
Bear case$54.55
Growth runs at half the analysts' path, 2% and 3%, the margin settles a fifth lower at 35.3%, and new capital earns only the 8% rate: the downturn test.
Our value$79.57
Revenue grows 4% and 6% over three years, the analysts' path (C55), then fades toward 4%, closing 30% of the gap each year; the margin moves to 44.1%, the analysts' year-three figure after stock pay and on the filed basis (3.7% less).
Bull case$115
Growth runs a quarter above the analysts' path, 5% and 7%, the margin reaches 48.5%, and new capital earns 11%.
What could go wrong
Every risk
The risks
Customers leaving faster
Corporate losses have risen every year since 2023 and reached 3.87% a month in September, against 2.73% a year earlier.
Growth that may be relabelled
In mid-2023 a product aimed at small businesses began booking as corporate, on a line the company itself draws.
Notes rest on one loan
The $348M of notes is due in 2028; a new $300M loan covers it and its tests leave room, but without goodwill it owes more than it owns.
One federal customer, held by another
The Veterans Affairs order belongs to a contractor, and Consensus holds no federal contract of its own.
What we still do not know
How much corporate growth is small businesses relabelled. The company reports one segment and sets the line itself.
How much of the Veterans Affairs money reaches Consensus. The order is renewed a year at a time and the company does not say.
What changes our view
Every route to a new view
Every route to a new view
→ Attractive
Corporate customers leave less than 3.5% a month, from 3.87%, while each pays more and corporate sales grow about 9% or faster.
→ Unattractive
The share price rises to about $95.48, 20% above what we think the business is worth.
→ Unattractive
Veterans Affairs stops buying the service, or the service loses its federal security approval. Debt net of cash tops $560M while the cash profit management promises is below $187M.
The next test
It supports the case if
Corporate monthly churn below 3.5%, revenue per corporate account at or above $302 and corporate revenue growth at or above 9%. That would mean the Q3 jump was a one-off from the new small-business accounts.
It pressures the case if
Corporate monthly churn at or above 3.5% for a second report (the criterion), or revenue per corporate account below $295, or SoHo's decline widening past 6%.
We would also be wrong if
Corporate customers leave at more than 3.5% a month in two reports running.
Total sales shrink on a year earlier for two quarters running.
The verdict
Scores and how we weighed it
The scores
Growth
2 of 4
Business quality
2 of 4
Financial position
3 of 4
Execution record
3 of 4
Per share capture
2 of 4
Potential
2 of 4
Risk profile
3 of 4
Valuation
4 of 4
Evidence quality
3 of 4
How we weighed it
ValueMixed
The price is about half our value and under the bear case, but both assume growth; with sales flat for ever the value sits only a little above the price.
BusinessNegative
Steady spare cash against a large debt, but corporate customers leave faster each year and a rival has matched its federal approval.
GrowthNegative
The value needs growth to return, while the thesis expects fax to shrink and the growth seen so far is mostly arithmetic.
RisksNegative
Corporate churn is at a series high, the corporate line is drawn by the company, the notes rest on one loan whose tests leave room, and the federal order is held by a contractor.
RivalsMixed
No listed rival compares directly; its main rival has matched the approval that set it apart.
The groupMixed
Software names move together on fears about AI; its own fact is the decline of fax, not the group's.
Latest newsNegative
Sales and cash held and the guide rose, but more corporate customers left and each paid less: the test went the wrong way.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.